专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

WO2012016145A2 MITOCHONDRIAL APOPTOSIS-INDUCED INFLAMMATION 审中-公开
标题翻译：麻醉诱导诱导的炎症
公开(公告)号：WO2012016145A2
公开(公告)日：2012-02-02
申请号：PCT/US2011045893
申请日：2011-07-29
申请人： CEDARS SINAI MEDICAL CENTER , SHIMADA KENICHI , ARDITI MOSHE
发明人： SHIMADA KENICHI , ARDITI MOSHE
IPC分类号： A61K31/708
CPC分类号： A61K31/708
摘要： Various embodiments of the present invention describe a method of treating inflammation, an inflammatory disease, an inflammatory disease condition and/or an autoimmune disease in a subject in need thereof. The method can comprise providing a composition comprising a mitochondrial apoptosis inhibitor or an oxidative nucleotide and administering the composition to the subject to treat the inflammation, the inflammatory disease, the inflammatory disease condition and/or the autoimmune disease. Various embodiments of the present invention is based on the mitochondria acting as a unifying point that integrates diverse NLRP3 stimuli and that mitochondrial dysfunction and apoptosis of macrophages are critical steps in various danger signal-induced NLRP3 inflammasome activation.
摘要翻译：本发明的各种实施方案描述了在有需要的受试者中治疗炎症，炎性疾病，炎性疾病状况和/或自身免疫性疾病的方法。该方法可以包括提供包含线粒体凋亡抑制剂或氧化核苷酸的组合物，并将该组合物施用于受试者以治疗炎症，炎性疾病，炎性疾病状况和/或自身免疫性疾病。本发明的各种实施方案基于线粒体，其作为整合不同NLRP3刺激的统一点，并且线粒体功能障碍和巨噬细胞的凋亡是各种危险信号诱导的NLRP3炎性体激活的关键步骤。

62. 发明申请

WO2011133692A1 BOOSTING IMMUNE DEFENSE BY UPREGULATING CCAAT/ENHANCER BINDING PROTEIN EPSILON 审中-公开
标题翻译：通过升级CCAAT /增强蛋白结合蛋白EPSILON来增强免疫力
公开(公告)号：WO2011133692A1
公开(公告)日：2011-10-27
申请号：PCT/US2011/033286
申请日：2011-04-20
申请人： CEDARS-SINAI MEDICAL CENTER , KOEFFLER, H., Phillip , LIU, George, Y. , THOENNISSEN, Nils , KYME, Pierre , GOMBART, Adrian, F.
发明人： KOEFFLER, H., Phillip , LIU, George, Y. , THOENNISSEN, Nils , KYME, Pierre , GOMBART, Adrian, F.
IPC分类号： A61K31/435 , A61K47/00
CPC分类号： A61K31/455 , A61K38/217 , Y02A50/47 , Y02A50/473 , Y02A50/481
摘要： The present invention demonstrates the important role of C/EBP ε in innate immune response against pathogens. Specifically, the inventors showed that in the absence of functional C/EBP ε , mice are severely impaired in their ability to clear S. aureus infection. Neutrophils are particularly affected, and susceptibility to S. aureus can be rectified by treatment with interferon-gamma (IFN-γ). Importantly, increased activity of C/EBP ε , either by induced overexpression of C/EBPE or by application of nicotinamide or an analog, derivative or salt thereof, dramatically enhances immune killing of S. aureus and leads to amelioration of infection.
摘要翻译：本发明证实了C / EBPe在针对病原体的先天免疫应答中的重要作用。具体地说，本发明人表明，在没有功能性C / EBPe的情况下，小鼠在清除金黄色葡萄球菌感染的能力方面严重受损。嗜中性粒细胞特别受影响，通过用干扰素-γ（IFN-γ）治疗可以矫正对金黄色葡萄球菌的易感性。重要的是，通过C / EBPE的诱导过表达或通过应用烟酰胺或其类似物衍生物或盐来增加C / EBPe的活性，显着地增强了金黄色葡萄球菌的免疫杀伤并导致了感染的改善。

63. 发明申请

WO2011116244A2 METHODS OF DIAGNOSING AND TREATING CONDITIONS ASSOCIATED WITH METABOLIC CLEARANCE RATE OF INSULIN 审中-公开
标题翻译：诊断和治疗与胰岛素代谢率相关的条件的方法
公开(公告)号：WO2011116244A2
公开(公告)日：2011-09-22
申请号：PCT/US2011/028902
申请日：2011-03-17
申请人： CEDARS-SINAI MEDICAL CENTER , UNIVERSITY OF SOUTHERN CALIFORNIA , GOODARZI, Mark, O. , TAYLOR, Kent, D. , ROTTER, Jerome, I. , BUCHANAN, Thomas, A.
发明人： GOODARZI, Mark, O. , TAYLOR, Kent, D. , ROTTER, Jerome, I. , BUCHANAN, Thomas, A.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/118 , C12Q2600/156
摘要： The present invention relates to methods of determining abnormal metabolic clearance rate of insulin (MCRI) and/or associated conditions in a patient. In one embodiment, the methods determine abnormal MCRI and/or associated conditions in a patient by determining the presence or absence of one or more MCRI genetic risk variants at the genetic locus of ADAMTSL3 and/or CMIP.
摘要翻译：本发明涉及确定患者的胰岛素异常代谢清除率（MCRI）和/或相关病症的方法。在一个实施方案中，所述方法通过确定在ADAMTSL3和/或CMIP的遗传基因座处存在或不存在一种或多种MCRI遗传风险变体来确定患者的异常MCRI和/或相关病症。

64. 发明申请

WO2011094722A1 USE OF TYROSINE KINASE INHIBITORS FOR TREATMENT OF CUSHING'S DISEASE AND HYPERCORTISOLISM 审中-公开
标题翻译：酪氨酸激酶抑制剂用于治疗丘疹病和高血压的使用
公开(公告)号：WO2011094722A1
公开(公告)日：2011-08-04
申请号：PCT/US2011/023247
申请日：2011-01-31
申请人： CEDARS-SINAI MEDICAL CENTER , FUKUOKA, Hidenori , MELMED, Shlomo
发明人： FUKUOKA, Hidenori , MELMED, Shlomo
IPC分类号： C12N9/12 , A61K38/45 , A61K31/535
CPC分类号： A61K31/535 , C12Q1/485 , G01N33/74 , G01N2500/10 , G01N2800/048
摘要： The invention relates to methods and kits for the treatment of, prevention of, and lowering the chances of developing Cushing's Disease and/or hypercortisolism by the administration of a tyrosine kinase inhibitor, such as gefitinib.
摘要翻译：本发明涉及通过施用酪氨酸激酶抑制剂如吉非替尼来治疗，预防和降低发展库兴氏病和/或高皮质醇血症的机会的方法和试剂盒。

65. 发明申请

WO2011088237A1 METHODS OF USING ZNF365 GENETIC VARIANTS TO DIAGNOSE CROHN'S DISEASE 审中-公开
标题翻译：使用ZNF365遗传变异体诊断克罗恩病的方法
公开(公告)号：WO2011088237A1
公开(公告)日：2011-07-21
申请号：PCT/US2011/021180
申请日：2011-01-13
申请人： CEDARS-SINAI MEDICAL CENTER , HARITUNIANS, Talin , ROTTER, Jerome, I. , TAYLOR, Kent, D. , TARGAN, Stephan, R.
发明人： HARITUNIANS, Talin , ROTTER, Jerome, I. , TAYLOR, Kent, D. , TARGAN, Stephan, R.
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6883 , C12Q2600/106 , C12Q2600/156 , C12Q2600/158 , C12Q2600/172
摘要： The present invention relates to prognosing, diagnosing and treating of Crohn's disease. The invention also provides prognosis, diagnosis, and treatment that are based upon the presence of one or more genetic risk factors at the ZNF365 genetic locus
摘要翻译：本发明涉及克罗恩病的预后，诊断和治疗。本发明还提供了基于在ZNF365遗传基因座上存在一种或多种遗传危险因素的预后，诊断和治疗

66. 发明申请

WO2011069120A1 METHOD AND SYSTEM FOR PLAQUE CHARACTERIZATION 审中-公开
标题翻译：方法和系统的PLAQUE特征
公开(公告)号：WO2011069120A1
公开(公告)日：2011-06-09
申请号：PCT/US2010/058979
申请日：2010-12-03
申请人： CEDARS-SINAI MEDICAL CENTER , DEY, Damini , SLOMKA, Piotr, J. , BERMAN, Daniel, S.
发明人： DEY, Damini , SLOMKA, Piotr, J. , BERMAN, Daniel, S.
IPC分类号： A61B5/05
CPC分类号： A61B6/504 , A61B6/032 , A61B6/503 , G06T7/0012 , G06T2207/10081 , G06T2207/30048 , G06T2207/30172
摘要： A method of quantifying plaques imaged by cardiac computed tomography angiography ("CCTA") scan data. Calcified and non-calcified component thresholds are determined based at least in part on attenuation values of a pool of blood in the CCTA scan data. An epicardial fat threshold is determined and used to classify epicardial fat in the CCTA scan data. A portion of CCTA scan data positioned between a detected outer boundary of the coronary artery and a portion classified as lumen is classified as arterial wall. NCP and CP seeds are identified in the arterial wall portion. Portions of the CCTA scan data continuous with a NCP seed and having attenuation values greater than an artery wall value and less than the NCP threshold are classified as NCP, and portions of the CCTA scan data continuous with the CP seed and having attenuation values greater than the CP threshold are classified as CP.
摘要翻译：定量通过心脏计算机断层摄影（“CCTA”）扫描数据成像的斑块的方法。钙化和非钙化组分阈值至少部分地基于CCTA扫描数据中血液池的衰减值来确定。确定心外膜脂肪阈值并用于对CCTA扫描数据中的心外膜进行分类。位于冠状动脉的检测到的外边界与被分类为管腔的部分之间的CCTA扫描数据的一部分被分类为动脉壁。在动脉壁部分中鉴定出NCP和CP种子。具有与NCP种子连续并具有大于动脉壁值且小于NCP阈值的衰减值的CCTA扫描数据的部分被分类为NCP，并且CCTA扫描数据的部分与CP种子连续并且具有大于 CP阈值被分类为CP。

67. 发明申请

WO2011069014A1 TOX3 AS A BIOMARKER FOR BREAST CANCER 审中-公开
标题翻译： TOX3作为乳腺癌的生物标志物
公开(公告)号：WO2011069014A1
公开(公告)日：2011-06-09
申请号：PCT/US2010/058795
申请日：2010-12-02
申请人： CEDARS-SINAI MEDICAL CENTER , KAYE, Jonathan
发明人： KAYE, Jonathan
IPC分类号： G01N33/48 , G01N33/53
CPC分类号： C07K16/18 , G01N33/57415 , G01N2800/50
摘要： The present invention relates to biomarkers useful for the diagnosis, prognosis and treatment of cancer. In an embodiment, the invention relates to the biomarker, TOX3. The inventive compositions and methods are also drawn to the use of anti-TOX3 antibodies and TOX3 nucleic acids and peptides for both detection and modulation of TOX3.
摘要翻译：本发明涉及可用于癌症的诊断，预后和治疗的生物标志物。在一个实施方案中，本发明涉及生物标志物TOX3。本发明的组合物和方法也被用于使用抗TOX3抗体和TOX3核酸和肽来检测和调节TOX3。

68. 发明申请

WO2010059806A3 GENERATION OF INDUCED PLURIPOTENT STEM CELLS WITHOUT THE USE OF VIRAL VECTORS 审中-公开
标题翻译：不使用病毒载体诱导的多功能干细胞的制备
公开(公告)号：WO2010059806A3
公开(公告)日：2010-07-15
申请号：PCT/US2009065117
申请日：2009-11-19
申请人： CEDARS SINAI MEDICAL CENTER , WHITE ANTHONY J , MAKKAR RAJ R , MARBAN EDUARDO
发明人： WHITE ANTHONY J , MAKKAR RAJ R , MARBAN EDUARDO
IPC分类号： C12N5/07 , C12N15/62
CPC分类号： C07K14/4702 , C07K2319/10 , C12N5/0696 , C12N2501/602 , C12N2501/603 , C12N2501/604 , C12N2501/605 , C12N2501/606 , C12N2501/608
摘要： Presented herein, generally, are methods for generating reprogrammed mammalian cells, e.g., induced pluripotent stem cells, from differentiated mammalian cells without the use of viral or plasmid vectors. In one aspect, the methods involve contacting a differentiated cell with transducible polypeptides comprising a reprogramming factor polypeptide linked to a cell penetration peptide so that a reprogrammed mammalian cell that exhibits at least one characteristic of pluripotency is generated. Also presented herein are methods for cardiac differentiation of a mammalian cell without the use of viral or plasmid vectors. In one aspect, such methods involve contacting a mammalian cell exhibiting at least one characteristic of pluripotency with a transducible polypeptide, so that cardiac differentiation of the cell occurs.
摘要翻译：本文一般公开了用于从分化的哺乳动物细胞产生重编程的哺乳动物细胞（例如诱导的多能干细胞）而不使用病毒或质粒载体的方法。一方面，所述方法包括使分化的细胞与包含与细胞穿透肽连接的重编程因子多肽的转导多肽接触，从而产生表现出多能性的至少一种特征的重编程哺乳动物细胞。本文还提供了在不使用病毒或质粒载体的情况下用于哺乳动物细胞的心脏分化的方法。一方面，此类方法涉及使展现出多能性的至少一个特征的哺乳动物细胞与转导多肽接触，从而发生细胞的心脏分化。

69. 发明申请

WO2010048415A1 METHODS OF USING JAK3 GENETIC VARIANTS TO DIAGNOSE AND PREDICT CROHN'S DISEASE 审中-公开
标题翻译：使用JAK3遗传变异体进行诊断和预测CROHN病的方法
公开(公告)号：WO2010048415A1
公开(公告)日：2010-04-29
申请号：PCT/US2009/061698
申请日：2009-10-22
申请人： CEDARS-SINAI MEDICAL CENTER , TAYLOR, Kent, D. , ROTTER, Jerome, I. , MEI, Ling , TARGAN, Stephan, R.
发明人： TAYLOR, Kent, D. , ROTTER, Jerome, I. , MEI, Ling , TARGAN, Stephan, R.
IPC分类号： C12Q1/68 , G01N33/68
CPC分类号： G01N33/6893 , C12Q1/6883 , C12Q2600/156 , C12Q2600/158 , G01N33/573 , G01N2333/91215 , G01N2800/065
摘要： The present invention relates to methods of diagnosing and diagnosing susceptibility to Crohn's Disease by determining the presence or absence of risk variants at the JAK3 locus. In one embodiment, the present invention provides a method of diagnosing susceptibility to Crohn's Disease by determining the presence of a risk variant at the JAK3 locus, where the risk variant is associated with positive expression of ASCA and/or anti-I2.
摘要翻译：本发明涉及通过确定在JAK3基因座处存在或不存在风险变异体来诊断和诊断克罗恩病易感性的方法。在一个实施方案中，本发明提供了通过确定在JAK3基因座处存在风险变体来诊断克罗恩病易感性的方法，其中所述风险变体与ASCA和/或抗-12的阳性表达相关。

70. 发明申请

WO2010033294A1 SHORT-FORM HUMAN MD-2 AS A NEGATIVE REGULATOR OF TOLL-LIKE RECEPTOR 4 SIGNALING 审中-公开
标题翻译：短型人MD-2作为类似受体4信号的负调节因子
公开(公告)号：WO2010033294A1
公开(公告)日：2010-03-25
申请号：PCT/US2009/050317
申请日：2009-07-10
申请人： CEDARS-SINAI MEDICAL CENTER , ARDITI, Moshe , GRAY, Pearl, S.
发明人： ARDITI, Moshe , GRAY, Pearl, S.
IPC分类号： C07K14/00 , A61K38/00
CPC分类号： C07K14/47 , A61K38/00 , C07K14/705
摘要： The present invention is based on a novel, alternatively spliced human isoform of MD-2 (MD-2s). In various embodiments, the invention relates to methods and kits for preventing, reducing the likelihood of developing and/or treating various conditions using MD-2s. The invention also describes methods of determining the risk of a subject to various conditions.
摘要翻译：本发明基于MD-2（MD-2）的新型可变剪接的人同种型。在各种实施方案中，本发明涉及用于使用MD-2s预防，降低开发和/或治疗各种病症的可能性的方法和试剂盒。本发明还描述了确定受试者在各种条件下的风险的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式